Siemens and LabCorp to co-develop clinical diagnostic tests
12 May 2008
Siemens Healthcare and Laboratory Corporation of America Holdings (LabCorp)
have announced that they are exploring possibilities to co-develop new
clinical diagnostic tests in the areas of companion diagnostics,
metabolic syndrome, oncology and diabetes.
Companion diagnostics are tests designed to identify the suitability
between patients and a particular drug therapy. The tests can be used in
personalized medicine to improve safety and efficacy of therapeutic
drugs and in some cases, may help determine optimal dosing for
Metabolic syndrome is becoming more common and is characterized by a
person having multiple risk factors that may include high blood
pressure, heart disease, obesity and diabetes, among others. It is
estimated that more than 50 million people are affected by this syndrome
in the United States alone .
Diabetes is a chronic disease currently affecting more than 180
million people worldwide and is likely to more than double by 2030 .
Early detection and treatment of diabetes may enable a patient to better
maintain their lifestyle. In addition, the possibility of advancing
early detection of cancer is important as it may lead to higher survival
rates. One in eight deaths worldwide is due to cancer, and in 2007,
there were more than 12 million estimated new cancer cases worldwide
Siemens is a leader in the diagnostic industry, while LabCorp is a
reference laboratory successfully serving more than 220,000 clients in
America. Together, the companies are well positioned to co-develop and
introduce new diagnostic tests that may advance patient care through
early detection and proper monitoring of disease.
"This agreement establishes a framework that gives both companies the
opportunity to offer new diagnostic tests to laboratories, physicians
and their patients more quickly and effectively than either could do
alone," said Dave Hickey, senior vice president strategic planning and
business development, Siemens Healthcare Diagnostics. "Advancing
healthcare for patients is an important commitment that we can reach
through strategic relationships such as this."
"LabCorp is excited about this strategic collaboration and its impact
on our companion diagnostics efforts," said Myla P Lai-Goldman, MD,
executive vice president, chief scientific officer and medical director
for LabCorp. "Alliances, such as this between developers and providers
of new tests, are critical in translating emerging biomarkers from
research into clinical practice."